Skip to content

SILYSTA: sector benchmark

Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.

Sector benchmark

SILYSTA

BE 0789.889.014
NACE 86.220, Specialist medical practice
NACE division 86, Human health activities all sizesfiscal years 2022 to 20258,892 to 19,634 sector peers per ratio

Summary

fiscal year 2025

SILYSTA does better than half of its sector on 6 of the 8 ratios compared.

most favourable quarter above the median below the median least favourable quarter
Strongest points
  • Long-term debt ratiobetter than 95%
  • Solvencybetter than 80%
  • Debt to equitybetter than 76%
Points to watch
  • Interest coveragebetter than 38%
  • Working-capital ratiobetter than 48%

Solvency and debt

How soundly the company is financed.
Solvency
87.3%▲2025

Solvency is above 80% of 19,634 sector peers: in the most favourable quarter.

Position against the sector improving since 2022.

2022202320242025
Debt to equity
0.15▼2025

Debt to equity is below 76% of 19,174 sector peers: in the most favourable quarter.

Position against the sector improving since 2022.

2022202320242025
Long-term debt ratio
0.00▼2025

The long-term debt ratio is below 95% of 8,892 sector peers: in the most favourable quarter.

Position against the sector improving since 2022.

2022202320242025
Interest coverage
29.00▲2025

Interest coverage is below 62% of 18,692 sector peers: less favourable than the median.

Position against the sector stable since 2022.

2022202320242025

Liquidity

Whether it can pay its short-term bills.
Current ratio
4.24▲2025

The current ratio is above 63% of 19,341 sector peers: more favourable than the median.

Position against the sector improving since 2022.

2022202320242025
Working-capital ratio
41.2%▲2025

The working-capital ratio is below 52% of 19,608 sector peers: less favourable than the median.

Position against the sector improving since 2022.

2022202320242025

Profitability

What the company earns on its assets and its sales.
Return on equity
33.8%▼2025

Return on equity is above 55% of 17,899 sector peers: more favourable than the median.

Position against the sector weakening since 2022.

2022202320242025
Return on assets
29.5%▲2025

Return on assets is above 68% of 19,601 sector peers: more favourable than the median.

Position against the sector improving since 2022.

2022202320242025

Not computable

Net margin, EBITDA margin, Gross margin, Days sales outstanding, Days payable outstanding, Days inventory. This company files the abbreviated or micro schema, in which turnover and purchases are optional; margins and credit terms therefore cannot be taken from its figures.

Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 28 September 2026 via checked.be.